These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31520524)

  • 1. Metformin treatment in young children with fragile X syndrome.
    Biag HMB; Potter LA; Wilkins V; Afzal S; Rosvall A; Salcedo-Arellano MJ; Rajaratnam A; Manzano-Nunez R; Schneider A; Tassone F; Rivera SM; Hagerman RJ
    Mol Genet Genomic Med; 2019 Nov; 7(11):e956. PubMed ID: 31520524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin as targeted treatment in fragile X syndrome.
    Dy ABC; Tassone F; Eldeeb M; Salcedo-Arellano MJ; Tartaglia N; Hagerman R
    Clin Genet; 2018 Feb; 93(2):216-222. PubMed ID: 28436599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases.
    Protic D; Aydin EY; Tassone F; Tan MM; Hagerman RJ; Schneider A
    Mol Genet Genomic Med; 2019 Jul; 7(7):e00745. PubMed ID: 31104364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of metformin in fragile X syndrome: An open-label study.
    Proteau-Lemieux M; Lacroix A; Galarneau L; Corbin F; Lepage JF; Çaku A
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110307. PubMed ID: 33757860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders.
    Gantois I; Popic J; Khoutorsky A; Sonenberg N
    Annu Rev Med; 2019 Jan; 70():167-181. PubMed ID: 30365357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral abnormalities in the Fmr1-KO2 mouse model of fragile X syndrome: The relevance of early life phases.
    Gaudissard J; Ginger M; Premoli M; Memo M; Frick A; Pietropaolo S
    Autism Res; 2017 Oct; 10(10):1584-1596. PubMed ID: 28590057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
    Berry-Kravis E
    Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular medicine of fragile X syndrome: based on known molecular mechanisms.
    Luo SY; Wu LQ; Duan RH
    World J Pediatr; 2016 Feb; 12(1):19-27. PubMed ID: 26547211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Treatments for Fragile X Syndrome.
    Johnson D; Clark C; Hagerman R
    Adv Neurobiol; 2023; 30():225-253. PubMed ID: 36928853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
    Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
    J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
    Çaku A; Pellerin D; Bouvier P; Riou E; Corbin F
    Am J Med Genet A; 2014 Nov; 164A(11):2834-42. PubMed ID: 25258112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin ameliorates core deficits in a mouse model of fragile X syndrome.
    Gantois I; Khoutorsky A; Popic J; Aguilar-Valles A; Freemantle E; Cao R; Sharma V; Pooters T; Nagpal A; Skalecka A; Truong VT; Wiebe S; Groves IA; Jafarnejad SM; Chapat C; McCullagh EA; Gamache K; Nader K; Lacaille JC; Gkogkas CG; Sonenberg N
    Nat Med; 2017 Jun; 23(6):674-677. PubMed ID: 28504725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from Fragile X Syndrome.
    Pellerin D; Lortie A; Corbin F
    Platelets; 2018 Mar; 29(2):113-124. PubMed ID: 28660769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9.
    Toledo MA; Wen TH; Binder DK; Ethell IM; Razak KA
    Behav Brain Res; 2019 Oct; 372():112068. PubMed ID: 31271818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensory Processing Phenotypes in Fragile X Syndrome.
    Rais M; Binder DK; Razak KA; Ethell IM
    ASN Neuro; 2018; 10():1759091418801092. PubMed ID: 30231625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.
    Farzin F; Perry H; Hessl D; Loesch D; Cohen J; Bacalman S; Gane L; Tassone F; Hagerman P; Hagerman R
    J Dev Behav Pediatr; 2006 Apr; 27(2 Suppl):S137-44. PubMed ID: 16685180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BDNF in fragile X syndrome.
    Castrén ML; Castrén E
    Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.
    Berry-Kravis EM; Lindemann L; Jønch AE; Apostol G; Bear MF; Carpenter RL; Crawley JN; Curie A; Des Portes V; Hossain F; Gasparini F; Gomez-Mancilla B; Hessl D; Loth E; Scharf SH; Wang PP; Von Raison F; Hagerman R; Spooren W; Jacquemont S
    Nat Rev Drug Discov; 2018 Apr; 17(4):280-299. PubMed ID: 29217836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aberrant behavior profile in Indonesian individuals with fragile X syndrome with limited genetic services.
    Winarni TI; Sumekar TA; Sarjana W; Hardian H; Hagerman RJ; Faradz SM
    Intractable Rare Dis Res; 2022 Nov; 11(4):215-218. PubMed ID: 36457587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin treatment for fragile X syndrome.
    Le Bras A
    Lab Anim (NY); 2024 Sep; 53(9):218. PubMed ID: 39215174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.